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Abstract
Background: Central precocious puberty is a condition characterized by precocious activation of the hypothalamic-
pituitary-gonadal axis. It may be idiopathic or secondary to organic causes, including syndromes such as
Neurofibromatosis type 1 (NF1).
Case presentation: We presented a girl of 6 years and 10 months with almost 11 café-au-lait skin macules, without
other clinical or radiological signs typical of NF1, and with a central precocious puberty. Genetic analysis evidenced
the new variant NM-152594.2:c.304delAp. (Thr102Argfs*19) in SPRED1 gene, which allowed to diagnose Legius
syndrome.
Conclusions: We report for the first time a case of central precocious puberty in a girl with Legius syndrome. The
presence of central precocious puberty in a child with characteristic café-au-lait macules should suggest
pediatricians to perform genetic analysis in order to reach a definitive diagnosis. Further studies on timing of
puberty in patients with RASopathies are needed to better elucidate if this clinical association is casual or secondary
to their clinical condition.
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Background
Precocious puberty (PP) is a condition characterized by
the appearance of pubertal signs before age 8 for girls
and age 9 for boys and is 8 times more frequent in fe-
males than in males [1–4]. Clinically, PP causes early de-
velopment of secondary sexual characteristics, rapid
bone maturation, increased growth velocity, behavioral
changes, inappropriate physical aspect for the chrono-
logical age, and reduction in adult height [4].
It is possible to distinguish a central precocious pu-
berty (CPP), GnRH-dependent, from a peripheral preco-
cious puberty (PPP), GnRH-independent. CPP is due to
a precocious activation of the hypothalamic-pituitary-
gonadal axis. Although it is frequently idiopathic, it
might also be secondary to organic causes, such as cen-
tral nervous system tumors, injury of the central nervous
system, genetic conditions or syndromes (e.g. neuro-
fibromatosis type 1 (NF1), Sturge-Weber syndrome, and
tuberous sclerosis) [1, 5]. Organic forms of CPP usually
start at a younger age than the idiopathic form, with a
more rapid progression. Yet, it is important to exclude
neurogenic causes, especially in boys, in which idiopathic
form is rarer than in girls [2–4].
In opposition to what happens with CPP, in PPP the
production of sexual steroids is independent from the
hypothalamic impulse. Some conditions that lead to
PPP, such as familial testotoxicosis, are typical of males,
others of females (ovarian cysts), finally there are forms
present in both sexes, such as congenital adrenal
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hyperplasia, McCune-Albright syndrome (MAS) and
hypothyroidism [3, 4].
Case presentation
A girl of 6 years and 10 months arrived to our Pediatric
Endocrinology Centre for a suspected PP. Parents are
not related, and no noteworthy disease was reported in
her familial history, in particular, no one in the family
presented disorders of the sexual development.
She was born at 39 weeks of gestational age by spon-
taneous delivery after an uneventful pregnancy. Birth
weight was 3210 g (− 0,01 standard deviations, [SD]),
birth length was 49 cm (− 0,21 SD), cranial circumfer-
ence was 32,5 cm (− 1,16 SD).
At birth, the presence of many café-au-lait skin
macules was detected, and this feature was reported in
her father and in her paternal grandmother too. For the
presence of these macules, she was submitted to derma-
tologic, neuropsychiatric and ophthalmologic evaluations
on clinical suspicion of NF1. Neuropsychiatric evaluation
did not detect any relevant neuro-behavioral problem,
apart from some difficulties in attention maintenance.
No dermatological or ocular signs associated with NF1
were reported. In addition, no noteworthy disease was
described in her clinical past.
Four months before our evaluation, parents detected
the appearance of bilateral thelarche, adult body odor
and leukorrhea. At our first clinical evaluation her
weight was 23.2 kg (− 0,23 SD), her height was 120.9 cm
(0 SD). Her growth velocity appeared accelerated
(approximately 1 cm/month; > 2 SD). Her Tanner’s stage
was T2, P1–2, A2. We found at least 11 café-au-lait skin
macules spread in torso, arms, neck and one in forehead,
with a variable diameter from 4mm to 17 mm. No
neurofibromas or freckles were detected. Her bone age
compared with Greulich & Pyle charts corresponded to
an age of 8 years and 6months.
Based on these clinical findings a stimulation test with
GnRH-analogue (triptorelin) was performed. Basal con-
centration of LH and FSH was 1,68 U/L, and 4,2 U/L
respectively. After 4 h, LH peak concentration was 35 U/
L while FSH peak concentration was 29,1 U/L. Basal es-
tradiol value was 176 pmol/L, estradiol peak was 186
pmol/L. According to these results, we confirmed a CPP.
Consequently, we started a treatment with GnRH-
analogue every 28 days, with good response.
To complete the diagnostic investigation a brain mag-
netic resonance imaging (MRI) was performed, which
did not present any trace of pathological findings, in
particular in the pituitary region and in the optic path-
way. Moreover, no cerebral sign of NF1 was evidenced.
However, in order to confirm (or disprove) the suspect
of NF1 we also performed genetic analysis. To identify
causative mutation on the NF1 gene, the genomic DNA
was extracted from peripheral blood leukocytes and
Targeted Next Generation Sequencing (NGS) was per-
formed. Given the normality of the NF1 gene, we ana-
lyzed the SPRED1 gene associated with the Legius
syndrome, in order to prove a possible differential
diagnosis.
This analysis identified the variant NM-152594.2:
c.304delAp. (Thr102Argfs*19) in SPRED1 gene. This
variant in SPRED1 is not reported in literature, but as
far as we can ascertain from the characteristics it pre-
sents, it probably has pathogenetic nature. This finding
finally brought to the diagnosis of Legius syndrome.
Discussion and conclusions
This is the first case of CPP in a patient with Legius syn-
drome. Initially we consider her CPP a consequence of a
suspected NF1; only afterwards, when a new mutation in
the SPRED1 gene was detected, it became possible to
conclude that she was affected by Legius syndrome.
Nowadays, it is still unknown whether Legius syndrome
can predispose to the development of CPP.
Legius syndrome is a rare genetic disease included in
RASophaties, a group of conditions caused by alterations
in RAS/MAPK pathway, among which the Noonan syn-
drome is the best known. NF1 is part of this group too
[5, 6]. The first case was identified by Brems in 2007 in a
patient with a similar-NF1 phenotype in which the gen-
etic analysis showed a loss-of-function mutation in SPRE
D1 gene [7]. This gene encodes Spred1, a protein
member of Sprouty/Spred family that acts as a negative
regulator in RAS/MAPK pathway. As a consequence of
this mutation, transmission of the signal is always active
[5, 6]. The inheritance of Legius syndrome is autosom-
inal dominant. It is estimated that approximately 1–4%
of people with café-au-lait skin macules has this syn-
drome [8, 9]. In addition to café-au-lait skin macules
and axillary or inguinal freckles, lipomas, macrocephaly,
learning difficulties, ADHD (Attention Deficit Hyper-
activity Disorder) and delay in neurobehavioral develop-
ment are described [8]. Our patient presented in fact a
mild disorder in attention maintenance, which might be
a misunderstood sign of her syndrome.
To date, no association between PP and Legius
syndrome is known. The role of pediatrician endocrinol-
ogists is essential first in recognizing a possible genetic
syndromic pathology from endocrinological symptoms
and secondly in managing the endocrinological compli-
cations of known genetic syndromes. The recognition
might be easy under some conditions, i.e. a possible
association between CPP and NF1, but more often, the
connection between endocrine features and genetic syn-
dromes remains unfamiliar, as in our clinical case [10].
In girls with clinical signs of PP it is necessary to verify
the activation of the hypothalamic-pituitary-gonadal axis
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in order to classify their condition as central or periph-
eral. Furthermore, attention must be paid to every clin-
ical element that can help to recognize a possible
associated genetic condition and to identify the etiology
of PP, such as visual deficit, headache, bone pain, bone
deformity or dermatologic findings. The coexistence of
cutaneous manifestation and clinical signs of PP suggests
the possible presence of NF1 or MAS. Whereas the
former condition is associated with CPP, the latter is as-
sociated with PPP [3, 4]. Moreover, these two clinical
conditions differ from each other in type, characteristics
and distribution of café-au-lait skin macules [11, 12]. On
the basis of these data, we promptly excluded the hy-
pothesis of MAS. Accordingly, a strong clinical suspect
of NF1 remained. In fact, café-au-lait skin macules asso-
ciated with Legius syndrome are clinically indistinguish-
able from those associated with NF1 as far as number,
pattern of distribution, or characteristics are concerned.
Moreover, patients with Legius syndrome, exactly like in
NF1, have axillary and/or inguinal freckling [11]. The
difference between these two syndromes resides in the
absence of neurofibromas, Lisch nodules, optic pathway
glioma, tibial dysplasia or central nervous system tumors
in cases of Legius syndrome [11, 12]. These data were
confirmed in our patient through brain MRI and oph-
thalmology evaluation, nevertheless it was only the gen-
etic analysis that allowed to achieve the definitive
diagnosis of Legius syndrome. Whereas CPP in patients
with NF1 was considered for years a complication re-
lated to optic pathway gliomas, due to the involvement
of the hypothalamic and sellar region [13], recent studies
have described some cases of children with NF1, CPP
and no cerebral lesions [14]. Therefore, in presence of a
girl with café-au-lait macules and CPP, clinicians should
take into consideration not only NF1 but also Legius
syndrome if not all NF1 diagnostic criteria are present.
Diagnosis of Legius syndrome has a different psycho-
logical impact compared to NF1, and permits to avoid
the psychological stress due to possible complications of
NF1, such as optic pathway glioma, learning difficulties,
social and emotional difficulties, skeletal problems, de-
velopment of neurofibromas [15]. Since the principal
complications associated with Legius syndrome concern
the neuro-behavioral field, once the diagnosis is certain,
it is recommended to begin a follow-up program in
order to identify any problems and intervene as soon as
possible. This will make possible to reassure parents that
neuro-behavioral development in patients with Legius
syndrome presents less severe problems than in patients
with NF1 [8, 16, 17].
We cannot consider PP as a feature of Legius syn-
drome, but the reported association between some
RASopathies and CPP supports a link between these
conditions, probably consequent to the involvement of
RAS-MAPK pathway. Past research has in fact described
cases of CPP in patients with RASophaties, in particular
with cardio-facio-cutaneous syndrome (having BRAF
mutation) [18] and with epidermal nevus syndrome
(having HRAS mutation) [19, 20]. More recently, clinical
studies have reported the cases of four patients, two with
Costello syndrome and two with cardio-facio-cutaneous
syndrome, who also presented CPP. In all of them, brain
MRI was performed and no abnormalities were found.
Nobody had hydrocephalus or ventriculomegaly, typical
characteristics of these syndromes, causing CPP [14, 21].
Consequently, it is possible to hypothesize a role of the
RAS-MAPK pathway in the genesis of CPP. It is in fact
known that the RAS-MAPK pathway is involved in the
regulation of the GnRH receptor signaling cascades.
GnRH receptor signaling results in secretion of LH and
FSH from the pituitary gland and stimulation of sex ster-
oid production by the gonads. Therefore, genetic abnor-
malities in this pathway could theoretically lead to
alterations during puberty, anyhow the exact mechanism
at the basis of the precocious activation of
hypothalamic-pineal-gonadal axis remains unclear [14,
21]. It is also possible that, in children with developmen-
tal delay, PP might occur as an indirect result of the
gene mutation and might derive from disease-associated
hypothalamic dysfunction, which could occur even with-
out causative structural brain abnormalities. Neverthe-
less, our patient is not classified as affected by
developmental delay but she only presents a mild dis-
order in attention maintenance. Therefore, according to
previous literature we suggest a detailed investigation of
the timing of puberty among patients with RASopathies
[18, 22, 23] and a special care for girls with Legius syn-
drome, in order to identify possible signs of PP.
In conclusion, we report for the first time a case of
CPP in a girl with Legius syndrome. In presence of CPP
in children with characteristic café-au-lait macules, we
suggest to perform genetic analysis in order to reach a
definitive diagnosis between NF1 and Legius syndrome.
Finally, further studies on timing of puberty in patients
with RASopathies are needed to better elucidate if this
clinical association is casual or secondary to their clinical
condition.
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